Sponsors / ACAD
ACAD

ACADIA Pharmaceuticals Inc.

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
19Trials in this database
8Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
ACP-104 in Acutely Psychotic Subjects With SchizophreniaNCT00490516ACADPhase 2Completed2008-02Actual
Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586ACADPhase 3Terminated2024-04-30Actual
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03575052ACADPhase 3Completed2022-05-06Actual
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03623321ACADPhase 3Completed2023-05-05Actual
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)NCT04181723ACADPhase 3Completed2021-10-28Actual
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeNCT04279314ACADPhase 3Completed2022-08-19Actual
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaNCT04531982ACADPhase 3Completed2024-01-25Actual
Open-Label Extension Study of Trofinetide for Rett SyndromeNCT04776746ACADPhase 3Terminated2023-06-30Actual
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeNCT04988867ACADPhase 2, Phase 3Terminated2023-05-31Actual
Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the KneeNCT05008835ACADPhase 2Terminated2022-10-06Actual
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderNCT05523895ACADPhase 2, Phase 3Completed2024-09-27Actual
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderNCT05555615ACADPhase 2, Phase 3Terminated2025-02-14Actual
ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673ACADPhase 2, Phase 3Recruiting2028-01Estimated
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06173531ACADPhase 3Active not recruiting2025-10Estimated
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyNCT06194799ACADPhase 3Enrolling by invitation2029-04Estimated
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06420297ACADPhase 3Terminated2025-12-19Actual
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisNCT07029581ACADPhase 2Recruiting2028-02Estimated
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisNCT07095465ACADPhase 3Enrolling by invitation2029-02Estimated
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseNCT07284667ACADPhase 2Recruiting2027-08Estimated

Latest recorded trial changes

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

NCT07284667 · ACADIA Pharmaceuticals Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 28

+ Updated value

measure: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Day 28

Check registry source · The saved outcome text may be shortened. Check the source for full wording.